In the rapidly evolving field of gene therapy, adeno-associated virus (AAV) vectors have emerged as a predominant vehicle for delivering therapeutic genes to faulty patient
target cells. The main modes of AAV production can be narrowed down to transient transfection, infection of insect Sf9 cells with baculovirus, and the use of stable producer cell lines. Among these, HEK293 cells combined with transient transfection remain the predominant choice in AAV production for their rapid development cycle, good productivity, scalability with consistent performance across scales, and proven regulatory pathway.
The successful production of AAV vectors relies heavily on the quality and efficiency of the AAV plasmids used in manufacturing. However, the substantial cost of plasmids presents a limitation in the transient transfection-based process.
This is where 3PBIOVIAN steps in with its exceptional expertise in AAV plasmids and in-house, high-yield manufacturing capabilities, tightly linked to the Design of
Experiments (DoE)-optimized AAVion® manufacturing platform. In this article, we will explore the building blocks of 3PBIOVIAN’s plasmid manufacturing capability, highlighting how our approach supports AAV programs by helping manage production costs while maintaining high productivity.
Transient Transfection- Flexible Necessity
Delivering plasmids into producer cells using a transfection reagent remains a method of choice for many gene therapy programs. Despite the availability of alternative production modes, transient transfection guarantees unparalleled flexibility and rapid
turnaround. It allows quick evaluation of different constructs and enables immediate initiation of production – an advantage when fast progression is crucial.
Despite common perceptions, transient transfection can be effectively scaled up. Recent advancements in bioreactor technologies and transfection reagents have significantly improved the scalability of transient transfection, making it a feasible option not only for R&D but also for clinical and even commercial-scale production. Cost-effectiveness for early-stage clinical trial stages is also essential, as production volumes are typically modest.
Generating stable cell lines is a time- and resource-intensive process, generally more suitable for the later-stage clinical journey and large-scale manufacturing. An
intermediate strategy involves the use of packaging cell lines to maintain helper and even capsid genes under tight regulatory control, using inducible systems such as TetR, LacI, or CymR.
AAV Plasmids: The Building Blocks Of Gene Therapy
Plasmids serve as the genetic backbone for packaging the therapeutic genes and regulatory elements. The most typical setup means delivery of three separate plasmids into the producer cell. The first plasmid carries the gene of interest (GOI) flanked by inverted terminal repeats (ITRs), which are essential for genome replication and
packaging into proteinous shell. The second, known as RepCap plasmid, encodes the AAV capsid proteins (VP1, VP2, and VP3) and regulatory genes such as Rep78, Rep66, Rep52, and Rep40, required for replication, as well as supporting elements, such as AAP, MAAP, and protein X. The third plasmid, often referred to as the helper plasmid,
provides adenoviral genes necessary for AAV vector production, including E2A, multiple genes under E4 block (notably essential E4orf6), and the VA RNA gene, essential in various steps ranging from synthesis, splicing, and prevention of AAV capsid
degradation.
3PBIOVIAN has carefully optimized its pHelper plasmid to remove any traces of structural genetic elements, such as Hexon, Penton, and Fiber, associated with especially immunogenic Knob domain. The direct aim was to increase safety and simplify and reduce construct size, improving overall plasmid production yields. By utilizing our AAV plasmids, clients gain access to verified gene sets optimized for
enhanced viral production and efficacy with freedom-to-operate (FTO) principles that boost innovation and unrestricted transfer. On-going internal work on vector optimization directs us to the two-vector system and beyond. We constantly improve our genetic repertoire to enhance the productivity, potency, and cost-effectiveness of our AAV production.
The Transformative Impact Of Unrestricted Plasmid Modification For Drug Development
At 3PBIOVIAN, we are committed to supporting the rapidly evolving gene therapy field with flexible, future-proof solutions. Moreover, a modern, end-to-end CDMO must remain agile and adaptable to quickly respond to constantly arising challenges across the development lifecycle. By moving beyond the limitations of restriction enzymes, advanced gene modification techniques now enable the rapid development of cutting-edge gene therapy products. Delivering solutions that allow quick, on-demand sequence modifications is another step forward to building a comprehensive end-to-end service package.
In-House High-Yield And High-Quality Plasmid Manufacturing
High-quality plasmids are an inseparable component of transfection-based AAV manufacturing. As critical raw materials, their characteristics hugely impact the overall yield and purity of the final AAV product. By controlling the entire plasmid
manufacturing process in-house, 3PBIOVIAN guarantees short lead times, eliminates dependency on external suppliers, and delivers extended supply chain stability and long-term project progression stability.
Our integrated manufacturing process and extensive GMP-grade production history ensure full compliance with stringent regulatory standards. While plasmid production represents a substantial cost factor in overall AAV production, our in-house model enables cost-effectiveness without compromising on quality.
Client-specific plasmid design and customization further enhance the value of our
service package. Combined with our new manufacturing facility where state-of-the-art technologies have been applied, we were able to obtain consistent and high-yield production of plasmids, enabling immediate transition to AAV production.
Freedom To Operate (FTO) Plasmids – Liberating Innovation
At any stage of drug development, potential legal concerns of IP infringement pose a substantial inconvenience or even danger. FTO plasmids present an ideal solution to enable open innovation and facilitate collaboration and sharing of resources among all stakeholders.
3PBIOVIAN’s FTO plasmids are free from third-party IP constraints, allowing their use across multiple jurisdictions without the need for country-specific patent
considerations. This facilitates global drug development programs and seamless transfer to alternative manufacturing sites. At 3PBIOVIAN, we are committed to empowering researchers and developers by removing legal barriers, enabling them to focus on innovation and accelerating the progress of gene therapies.
GMP And HQ Manufacturing: Ensuring Regulatory Compliance And Highest Standards
Plasmids are considered critical starting materials in AAV manufacturing, as they have a significant impact on the quality and safety of the final gene therapy product. With
over 20 years of experience and adherence to Good Manufacturing Practices (GMP), 3PBIOVIAN ensures reliable production of high-quality plasmids.
We offer plasmid qualities ranging from Research-grade (RG) through High-Quality (HQ) and GMP-grade, each fitting better a different stage of drug development with varying levels of quality control stringency. The Research-grade (RG) plasmids allow rapid delivery time and are especially convenient for discovery and R&D phase. The HQ-grade plasmids can be used in the early phases of clinical studies, and the GMP grade plasmids are suitable for Phases II and III, as well as commercial stages.
The GMP-grade adds on top of HQ-grade qualities a Master Cell Bank (MCB), qualified vendors for raw materials, stringent environmental controls, and oversight by a
dedicated Quality Assurance (QA) team. These elements ensure comprehensive traceability and regulatory compliance.
At 3PBIOVIAN, GMP compliance goes beyond regulatory requirements – it serves as a cornerstone of our commitment to delivering safe and effective products. By adhering to rigorous protocols and quality standards, 3PBIOVIAN safeguards that the plasmids meet regulatory requirements, reduce risk, and accelerate the path from clinical development to commercialization.
Collaboration And Customer Support Is A Key
We believe that scientific and technological expertise alone is not enough. Fostering strong relationships and collaboration with our clients is key to the success of every gene therapy program. A strong collaborative spirit with our partners and clients is the path for programs to succeed. We face challenging biology, complex mammalian cell-based production processes, and diverse chemistry and biological nuances of gene
therapies. While we navigate through process scales, our shared goal is to maintain and increase productivity. By combining client insight and 3PBIOVIAN technical expertise
perspectives we come together to right decisions driving optimal outcomes.